Category: Diabetes

1. What should patients with diabetes know about COVID-19 and how it may affect them?

Those people who are at the highest risks of contracting covid-19, are those over the age 65, have heart disease, liver disorders, diabetes and other underlying health issues. Because it effects the immune system and compromises the bodies natural defenses fight off infections, it is critical for a person with diabetes to have good blood flow circulation, reducing the chance of infection, ulcers and at worse case amputations.

2. How does Circularity’s  over-the-counter (OTC) transdermal device helps patients with foot issues, potentially including COVID?

D’OXYVA®  (deoxyhemoglobin vasodilator) is validated to significantly improve macro- and micro-circulation of blood flow and certain nerve activities in the body, which together are widely reported to form an effective non-invasive, pain-free solution option for many conditions. It provides accelerated and comprehensive wound care — plus infection protection — in a painless, affordable non-prescription solution available in a clinical setting, or in the comfort and privacy of your own home.

D’OXYVA has shown significant promise for severe cases of diabetic foot ulcers. Its therapeutic effects have circulatory and neurological benefits as well.

3. Tell us about CO₂, microcirculation, and its effects on the body.

D’OXYVA uses ultra-purified carbon dioxide, which has been shown to produce higher oxygen unloading by hemoglobin, thereby increasing oxygen-rich blood flow in the local microcirculatory system. This improved dermal microcirculation leads, in turn, to enhanced wound healing.

Good blood circulation has many important health benefits. Among the most prominent is the optimal oxygenation of bodily tissues and organs, which allows for efficient functioning of the heart, lungs and muscles. Active blood circulation also improves the immune response against disease by allowing the better transportation of white blood cells throughout the body. Furthermore, proper blood circulation improves cellular detoxification, while waste removal becomes more efficient. Among its other health benefits, D’OXYVA^® has been also validated as a successful means of improving the autonomic nervous system.

4. What have clinical trials shown about how this device helps patients, especially diabetics with foot problems?

Studies with D’OXYVA have shown increased oxygen concentration and lower carbon dioxide concentration in the blood just 30 minutes after treatment that can last upto 60 minutes. Over two dozen studies demonstrated convincing results at clinics and at home with no adverse events.

Many treatments make bold online claims to help cure various conditions and restore you to health — pills, shots, creams, procedures, and devices. But only science-backed, one-of-a-kind D’OXYVA stands alone, delivering the remarkable physical, mental, and emotionally rejuvenating results.

5. As a Internist ­focused on prevention, what do you want diabetics to know about making their foot health a priority?

The heart is the engine that makes the body function. The foot though a far distance from the heart requires consistent blood flow. It requires open pathways. If those pathways are constricted, which is fairly normal occurrence with diabetic patients, those areas have a tendency to die off, because of the poor blood circulation. That is why it is key to some type of vasodilation to promote microcirculatory blood flow to supply adequate oxygenation the the feet. There by likely helping to prevent infections, ulcers and wounds.

1. What should patients with diabetes know about COVID-19 and how it may affect them?

In the middle of a global pandemic, like the one we’re living, it is very important to be able to assess risks and try to diminish their effects. Cardiovascular disease is one of the most relevant and impactful; that is why improving blood flow and tissue oxygenation is so important for improving the health outcomes of a COVID-19 infection.

People with diabetes, especially those over 65 years of age, have been shown to be affected more often and with greater severity by coronavirus infection. Diabetic patients, particularly those with more longstanding and poorly controlled disease, suffer from diminished oxygen-rich blood in their microcirculation, which may be a major risk factor for why COVID is so deadly for them. Reports from Chinese authorities and from top American institutions, such as Harvard Medical School, show that underlying cardiovascular disease is associated with an increased risk of in-hospital death for patients hospitalized with COVID-19.

2. How does Circularity’s  over-the-counter (OTC) transdermal device helps patients with foot issues, potentially including COVID?

D’OXYVA^® (deoxyhemoglobin vasodilator) is a groundbreaking noninvasive, painless transdermal delivery system based on widely established, groundbreaking, Nobel Prize-winning science and is shown to increase oxygen-rich blood flow in the local microcirculatory system, which in turn leads to better blood perfusion and tissue oxygenation. The increased peripheral perfusion plays a significant role in enhancing the wound healing process, which may lead to a reduction in the influence of preexisting conditions in cases of a coronavirus infection.

D’OXYVA has shown significant promise for severe cases of diabetic foot ulcers. Its therapeutic effects have circulatory and neurological benefits as well.

3. Tell us about CO₂, microcirculation, and its effects on the body.

D’OXYVA uses ultra-purified carbon dioxide (CO₂), a naturally occurring nontoxic substance, which is delivered via the D’OXYVA noninvasive skin delivery system. The CO₂ acts as a signaling agent for the body to help stimulate delivery of red blood cells loaded with fresh oxygen to the peripheral tissue. D’OXYVA’s over-the-skin route of administration has demonstrated a safer, more effective alternative route to inhalation — a routine CO₂ delivery method in hospitals. Purified carbon dioxide is a nontoxic molecule and can be sold by Circularity over the counter (OTC) and online without the need for a prescription. Circularity’s products are manufactured in compliance with the highest standards.

Improved microcirculation leads to better tissue oxygenation and better heart function, as the heart does not need to exert extra force to propel the blood to all the organs of the body.

4. What have clinical trials shown about how this device helps patients, especially diabetics with foot problems?

Over two dozen studies have demonstrated convincing results at clinics and in homes with no adverse events. D’OXYVA has recorded significant results, delivering major outcomes for well over 90% of users. Studies of D’OXYVA have shown unmatched results in noninvasive wound care — particularly when all other approaches have failed. D’OXYVA provides an adjunct to accelerate comprehensive wound care programs and infection protection in a painless, affordable nonprescription solution that is available in a clinical setting or in the comfort and privacy of your own home.

In an ongoing multiyear, multicountry, multicenter randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA demonstrated hastened wound improvement and eventual wound closure in an average of 5 weeks**.

In addition, D’OXYVA eliminated pain and improved quality of life such as in regard to sleep, appetite, and mood in just a week in 100% of subjects.

No adverse events of any kind were reported during and for years after the studies.

5. As a Internist ­focused on prevention, what do you want diabetics to know about making their foot health a priority?

Microcirculation is often disregarded by diabetic patients, and I’d like to emphasize to them that microcirculation is important, especially in wound healing. In other words, microcirculation is the bridge between blood and single cells that supply oxygen and nutrients to human tissues, especially where it is needed the most. Without proper blood flow, their body will be prone to more complications, including the development of foot ulcers that could lead to amputation. Remember that having improved microcirculation and oxygenation promotes faster wound healing, promotes better performance, and enhances the renewal and replacement of damaged tissues.

1. What should patients with diabetes know about COVID-19 and how it may affect them?

COVID-19 can infect people of all ages. However, two groups are at higher risk of developing severe complications secondary to COVID-19. These are older adults (over 60 years old) and individuals with underlying medical conditions such as obesity, cancer, diabetes, cardiovascular disease, and chronic respiratory disease. Because diabetic patients often have multiple comorbidities, such as obesity and cardiovascular disease, new data suggests that the death rate and hospitalization duration are four times higher for this subset of the population.

2. How does Circularity’s  over-the-counter (OTC) transdermal device helps patients with foot issues, potentially including COVID?

Disseminated intravascular coagulation (DIC) is one of the severe complications related to COVID-19. This is a serious disorder in which the proteins that control blood clotting become overactive, which can result in symmetrical peripheral gangrene. The Circularity OTC device is a novel transdermal delivery system that can deliver carbon dioxide directly to body tissues low in oxygen. Further studies are needed, but this device has the potential to prevent symmetrical peripheral gangrene, a limb-threatening complication of COVID-19.

3. Tell us about CO₂, microcirculation, and its effects on the body.

Inadequate wound healing in chronic wounds is secondary to poor blood perfusion at the level of the wound and surrounding tissues, defined as local hypoxia. Transdermal delivery of carbon dioxide has therapeutic effects on both the microcirculation and tissue oxygenation. By improving tissue oxygenation and microcirculation, studies have shown greater progress in wound healing with respect to wound size and area of injury.

4. What have clinical trials shown about how this device helps patients, especially diabetics with foot problems?

Among patients with diabetes, 15% develop a foot ulcer, and 12-24% of individuals with a foot ulcer require amputation. The average cost of treatment ranges from $16,500 for patients without severely impaired circulation to about $63,000 for patients undergoing an amputation. Capillary microcirculation to foot skin has shown signs of significant impairment in diabetic patients when metabolic control is poor, resulting in poor healing rates for ulcers and worsening of diabetic peripheral neuropathy. The preliminary studies of the Circularity OTC medical device have shown increased oxygenation to tissue, resulting in improved wound healing.

5. As a Internist ­focused on prevention, what do you want diabetics to know about making their foot health a priority?

During the COVID-19 pandemic, it has become even more imperative for diabetic patients to avoid hospitalization from foot complications. To prevent foot complications, diabetic patients must continue to control their diabetes, look at their feet on a daily basis, and become comfortable with using telemedicine to communicate their medical needs to their physicians. During their daily exam, diabetics should look for blisters, minor injuries, sores, and any other abnormal changes to their feet. By following these simple steps, they can reduce the risk of foot complications and amputations.